Soleno Therapeutics INC 10-Q quarterly reports

Soleno Therapeutics announces significant revenue growth and profitability in Q1 2026, driven by VYKAT XR sales, while also entering into a merger agreement with Neurocrine Biosciences.

Soleno Therapeutics achieved profitability in Q3 2025 driven by strong initial sales of its newly FDA-approved drug VYKAT XR for Prader-Willi syndrome, despite a net loss for the nine-month period.

Soleno Therapeutics, Inc. announced its first product revenue of $32.7 million from VYKAT XR sales following FDA approval, significantly reducing its net loss for the quarter.

Soleno Therapeutics announces its first quarter 2025 results, highlighting the FDA approval and initial prescriptions of VYKAT XR for Prader-Willi syndrome.

Soleno Therapeutics' Q3 2024 report reveals a significant increase in operating expenses, primarily driven by research and development and general and administrative costs, as the company advances its lead drug candidate, DCCR, towards potential FDA approval.

Soleno Therapeutics reports a net loss of $43.3 million for the first half of 2024, driven by increased research and development and general administrative expenses, while also submitting a New Drug Application (NDA) for its lead candidate.

Soleno Therapeutics reported a net loss of $21.4 million for the first quarter of 2024, while progressing its lead candidate DCCR towards a New Drug Application submission.